Pfizer Inc.

NYSE:PFE  
51.72
-0.06 (-0.12%)
7:59:45 PM EDT: $51.76 +0.04 (+0.08%)
Products

Pfizer And BioNTech Submit Application To U.S. FDA For Emergency Use Authorization Of Omicron Ba.4/Ba.5-Adapted Bivalent Vaccine Booster In Children 5 Through 11 Years Of Age

Published: 09/26/2022 10:56 GMT
Pfizer Inc. (PFE) - Pfizer and Biontech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.
4/ba.
5-adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age.
Biontech - Application to Extend Omicron Ba.
4/ba.
5-adapted Bivalent Vaccine Marketing Authorization in Eu to Include 5-11 Years Children to Be Submitted to Ema in Coming Days.